The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, multicenter, phase III study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving doxorubicin-cyclophosphamide/epirubicin-cyclophosphamide (AC/EC) based highly emetogenic chemotherapy: CONSOLE-BC.
 
Junji Tsurutani
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Lilly
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Kirin (Inst); Lilly (Inst); MSD Oncology (Inst); Nihonkayaku (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Chugai Pharma; Daiichi Sankyo; Novartis
 
Kazuo Matsuura
No Relationships to Disclose
 
Kenichi Inoue
Honoraria - Chugai Pharma; Eisai; Lilly; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); PAREXEL (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Yuko Tanabe
Honoraria - Daiichi Sankyo; Pfizer
 
Tetsuhiko Taira
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly; Taiho Pharmaceutical
 
Kaoru Kubota
Consulting or Advisory Role - Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst)
 
Tomohide Tamura
Honoraria - Boehringer Ingelheim; Chugai Pharma; CMIC; Lilly; MSD; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical
 
Toshiaki Saeki
Research Funding - Eisai (Inst); Taiho Pharmaceutical (Inst)